
Arvinas Investor Relations Material
Latest events

Study Update
Arvinas
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Arvinas Inc
Access all reports
Arvinas Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of cancer and other diseases. Utilizing its proprietary PROTAC® (Proteolysis Targeting Chimera) technology, Arvinas aims to degrade disease-causing proteins, which is a novel approach in the field of drug development. This technology harnesses the body's natural protein disposal system to selectively and efficiently remove aberrant proteins. The company's pipeline includes therapies targeting a range of diseases with significant unmet medical need, emphasizing oncology and neuroscience. The company is headquartered in New Haven, Connecticut, and its shares are listed on the NASDAQ.
Key slides for Arvinas Inc


Study Update
Arvinas Inc


Study Update
Arvinas Inc
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
ARVN
Country
🇺🇸 United States